TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02711267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Zovirax® cream
Description: (manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Zovirax® cream
Description: (manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Zovirax® cream
Description: (manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Zovirax® cream
Description: (manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Aciclostad cream
Description: (STADA Arzneimittel GmbH, Vienna, Austria)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Aciclovir cream 1A Pharma
Description: (1A Pharma GmbH, Vienna, Austria)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Aciclovir cream 1A Pharma
Description: (1A Pharma GmbH, Vienna, Austria)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Aciclovir cream 1A Pharma
Description: (1A Pharma GmbH, Vienna, Austria)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Zovirax Cold Sore Cream
Description: (GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
Study: NCT03473132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: four factor prothrombin complex concentrate
Description: After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
Study: NCT03976622

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Blood samples: serum and PBMC

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Blood samples: serum and PBMC
Study: NCT02711267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Zovirax® cream (Austria)
Description: (GlaxoSmithKline Pharma GmbH, Vienna, Austria)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OFM
Description: Sampling method for interstitial fluid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OFM
Description: Sampling method for interstitial fluid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OFM
Description: Sampling method for interstitial fluid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OFM
Description: Sampling method for interstitial fluid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Probe
Description: Sampling probe used during OFM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Probe
Description: Sampling probe used during OFM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Probe
Description: Sampling probe used during OFM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Probe
Description: Sampling probe used during OFM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Pump
Description: Pump used to operate OFM probes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Pump
Description: Pump used to operate OFM probes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Pump
Description: Pump used to operate OFM probes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Pump
Description: Pump used to operate OFM probes
Study: NCT03968640

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10
Description: The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
Study: NCT00446680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: 400mg BD for 6 months followed by a 6 month open label period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo BD for 6 months
Study: NCT04621383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein plus collagen
Description: This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey protein plus maltodextrin
Description: This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
Study: NCT00927914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranirestat
Description: Ranirestat 40 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranirestat
Description: Ranirestat 40 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study: NCT02375061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-BPS

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Activities
Study: NCT01437475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac
Description: 10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
Study: NCT02051933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U
Study: NCT00550641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: physical therapy in warm pool performing stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: physical therapy in warm pool performing Ai Chi
Study: NCT04561726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation
Description: Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
Study: NCT04561726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
Study: NCT01779817

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
Study: NCT00921895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RPS Adeno Detector IV
Description: One time test with the RPS Adeno Detector IV
Study: NCT00581880

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
Study: NCT00391209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals,6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 6 months
Study: NCT01934647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892
Description: Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892
Description: Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892
Description: Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
Study: NCT00724711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
Description: FTC 200 mg/TDF 300 mg tablet, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir (ABC)/lamivudine (3TC)
Description: ABC 600 mg/3TC 300 mg tablet, once a day
Study: NCT05576545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Breast Cancer Self-Care App
Description: The Breast Cancer Self-Care App includes several parts- introduction to breast cancer, types of treatment, side effects care, nutrition, relaxation videos, insurance, medical news and recording side effects, etc. The researcher assisted in installing the App on the patient's mobile phone, entered the personal account, and asked the patient to fill in questionnaires. Patients were given individual health education task in the Breast Cancer Self-Care App every week according to the type of chemotherapy drugs. After four weeks, they filled in questionnaires again.
Study: NCT03976622

Intervention type: BIOLOGICAL
Intervention: Skin biopsies
Description: These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.

Intervention type: BIOLOGICAL
Intervention: Skin biopsies
Description: These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.

Intervention type: BIOLOGICAL
Intervention: Skin biopsies
Description: These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
Study: NCT02044107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-packaging and counseling messages
Description: The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc \& ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc \& antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
Study: NCT03496779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin - induction
Description: Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
Study: NCT03976622

Intervention type: BIOLOGICAL
Intervention: Skin biopsies
Description: These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
Study: NCT02903537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
Description: Intranodal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
Description: Intranodal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
Description: Intranodal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
Description: Intranodal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta
Description: Subcutaneous administration interferon-beta
Study: NCT01469559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novolin Toronto insulin
Description: Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
Study: NCT03246100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
Study: NCT02393157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
Study: NCT03496779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin - maintenance
Description: Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous or allogeneic stem cell transplantation
Description: Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
Study: NCT00974584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n
Study: NCT02199899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIF 1149 BS - single rising doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00974584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter\*minute (mg/mL\*min).\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter\*minute (mg/mL\*min).\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of every 3-week cycle.\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of every 3-week cycle.\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV on Day 1 of every 3-week cycle.\\n\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV on Day 1 of every 3-week cycle.\\n\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed 500 mg/m\^2 IV on Day 1 of every 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed 500 mg/m\^2 IV on Day 1 of every 3-week cycle.
Study: NCT06199583

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear-wave elastography
Description: Ultrasound shear-wave elastography

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear-wave elastography
Description: Ultrasound shear-wave elastography